Artivion (NYSE:AORT - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports. They presently have a $34.00 price objective on the stock. Needham & Company LLC's price target indicates a potential upside of 9.78% from the company's current price.
Other analysts also recently issued reports about the company. Oppenheimer increased their price target on Artivion from $30.00 to $32.00 and gave the stock an "outperform" rating in a report on Friday, November 8th. JMP Securities restated a "market outperform" rating and set a $33.00 price target on shares of Artivion in a report on Tuesday, December 10th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $31.80.
View Our Latest Stock Analysis on Artivion
Artivion Trading Down 1.3 %
AORT stock traded down $0.40 during trading on Tuesday, hitting $30.97. The company had a trading volume of 301,706 shares, compared to its average volume of 349,124. The stock has a market cap of $1.30 billion, a PE ratio of -1,548.60 and a beta of 1.74. The business has a 50-day moving average of $29.40 and a 200-day moving average of $27.41. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. Artivion has a one year low of $16.48 and a one year high of $32.33.
Insider Transactions at Artivion
In related news, SVP Jean F. Holloway sold 8,070 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total value of $243,068.40. Following the completion of the sale, the senior vice president now directly owns 153,862 shares of the company's stock, valued at approximately $4,634,323.44. This represents a 4.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Amy Horton sold 4,329 shares of Artivion stock in a transaction on Friday, December 6th. The stock was sold at an average price of $29.66, for a total transaction of $128,398.14. Following the transaction, the chief accounting officer now directly owns 135,660 shares in the company, valued at $4,023,675.60. This represents a 3.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 20,017 shares of company stock valued at $600,007 over the last ninety days. 8.10% of the stock is owned by company insiders.
Hedge Funds Weigh In On Artivion
Hedge funds have recently modified their holdings of the company. FMR LLC lifted its holdings in Artivion by 28.0% during the third quarter. FMR LLC now owns 115,184 shares of the company's stock worth $3,066,000 after acquiring an additional 25,176 shares during the period. Barclays PLC boosted its holdings in shares of Artivion by 346.3% in the 3rd quarter. Barclays PLC now owns 70,877 shares of the company's stock worth $1,888,000 after buying an additional 54,996 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in Artivion during the third quarter worth about $5,798,000. JPMorgan Chase & Co. raised its position in Artivion by 394.9% in the third quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company's stock worth $2,606,000 after acquiring an additional 78,120 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Artivion by 58.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company's stock valued at $9,074,000 after acquiring an additional 125,668 shares during the period. Institutional investors own 86.37% of the company's stock.
Artivion Company Profile
(
Get Free Report)
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Featured Articles
Before you consider Artivion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artivion wasn't on the list.
While Artivion currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
